Free shipping on orders over $149
SafeRxPills - Online Pharmacy
These products are intended for personal use only. We are not licensed by the FDA.

Flohale 0.5 Respules

Generic: Fluticasoneby Cipla Limited

Buy Flohale 0.5 Respules (Fluticasone) online | SafeRxPills

Strength

Select pack size

1
Free shipping over $149
Free reshipment if lost
Discreet packaging
WHO-GMP certified
Secure checkout

Similar medicines

View all
Buy Allegra Nasal Spray (Fluticasone) online | SafeRxPills

Allegra Nasal Spray

$21.00View
Buy Flomist Nasal Spray (Fluticasone) online | SafeRxPills

Flomist Nasal Spray

$24.00View
Buy Flutivate Cream (Fluticasone) online | SafeRxPills

Flutivate Cream

$25.00View
Buy Allegra Nasal Duo (Fluticasone/Azelastine) online | SafeRxPills

Allegra Nasal Duo

$22.00View

About Flohale 0.5 Respules

Flohale 0.5 Respules are single-dose plastic ampoules of fluticasone propionate nebuliser suspension made in India by Cipla. Indian pharmacy listings give each respule as fluticasone propionate 0.5 mg in 2 mL, sold in packets of 5 (Apollo, PharmEasy, Truemeds). Fluticasone propionate is an inhaled corticosteroid: a preventer that calms inflammation in the airways when it is used every day, breathed in as a mist through a jet nebuliser. We sell packs of 20, 40 and 60 respules, from $1.77 a respule in the 60 pack.

This page covers who the UK label licenses the nebuliser form for, how many respules a day its doses add up to, how to use it with a nebuliser, side effects including adrenal and growth effects, when to get urgent help, who should not use it and the price per respule. Clinical figures come mainly from the UK product information for Flixotide Nebules 0.5 mg/2 ml (GSK), the reference product for this form, listed at the end. We have not found a published study comparing Flohale respules with Flixotide Nebules.

Flohale is not a reliever. The UK label says Flixotide Nebules "are not designed to relieve acute symptoms for which an inhaled short-acting bronchodilator is required" and "are not a substitute for injectable or oral corticosteroids in an emergency (i.e. life threatening asthma)". Anyone using it needs a fast-acting reliever, such as salbutamol, for sudden symptoms.

Flohale 0.5 Respules at a glance

Active ingredientFluticasone propionate 0.5 mg per 2 mL respule, as listed by Indian pharmacies
Brand and makerFlohale, by Cipla Limited, India (PharmEasy gives a Cipla site in Rangpo, Sikkim)
FormNebuliser suspension in single-dose respules; needs a jet nebuliser and compressor (the UK label says ultrasonic nebulisers are "not generally recommended")
Regulatory statusUS and Canada: fluticasone propionate nebuliser suspension is not approved (Drugs@FDA and Health Canada's Drug Product Database list no fluticasone propionate nebuliser product). UK: licensed as Flixotide Nebules, but the NHS dictionary of medicines lists the GSK 0.5 mg pack as discontinued and not available. Australia: healthdirect lists Flixotide Nebules 0.5 mg/2 mL as a prescription medicine; we could not confirm current supply. This Indian Flohale pack is not registered with the FDA, MHRA, TGA or Health Canada.
Usual dose from the UK labelAdults and adolescents over 16 (severe chronic asthma): 500 to 2000 micrograms twice daily, which is 1 to 4 respules twice a day. Children 4 to 16 (flare-ups of asthma only): 1000 micrograms twice daily, which is 2 respules twice a day.
Time to benefitUK leaflet: "It takes a few days for this medicine to work". Irish label: maximal improvement may be reached within 4 to 7 days.
Packs20, 40 and 60 respules
Price per respule$2.25 (20 pack), $1.81 (40 pack) and $1.77 (60 pack), before shipping
Delivery7 to 14 business days to the US, UK, Australia and Canada; $25 shipping under $149, free from $149

Price per respule

Prices below are as of October 2026. The pack selector above always shows the current price.

PackPricePer respuleShippingPer respule with shippingLasts at 2 a day (lowest adult dose)Lasts at 4 a day (child flare-up dose)
20 respules$45.00$2.25$25$3.5010 days5 days
40 respules$72.50$1.81$25$2.4420 days10 days
60 respules$106.25$1.77$25$2.1930 days15 days

The last two columns are our own arithmetic, not label figures. Two respules a day is 500 micrograms twice daily, the lowest adult dose in the UK label; 4 a day is the UK dose for children aged 4 to 16 (1000 micrograms twice daily). At the top adult dose (2000 micrograms twice daily, 8 respules a day) a 60 pack lasts about 7 days. For the top adult dose (2000 micrograms twice daily), Cipla also makes Flohale 2mg Respules, which are in our range; a 2 mg respule is not a substitute for a 1 mg dose.

All three packs are under the $149 free shipping threshold. The 60 pack is the cheapest per respule both before and after shipping. The smallest order of this product that reaches $149 is a 60 pack plus a 20 pack ($151.25 for 80 respules, about $1.89 each with free shipping, our arithmetic). Do not buy more than your prescription covers: check the expiry date when your order arrives.

Compared with Flixotide Nebules and US options

Flohale 0.5 RespulesFlixotide Nebules 0.5 mg/2 ml (UK)US budesonide inhalation suspension 0.5 mg/2 mL (a different steroid)
MakerCipla, IndiaGSK (Glaxo Wellcome UK)Several makers, including Teva, Amneal and Cipla USA
Dose and fillFluticasone propionate 0.5 mg in 2 mL (Indian listings)Fluticasone propionate 0.5 mg in 2 mLBudesonide 0.5 mg in 2 mL
StatusNot registered in the US, UK, Australia or CanadaUK licence PL 10949/0297; NHS dm+d lists the pack as discontinued and not availableFDA approved, for children 12 months to 8 years
Price per respule (ours) or US pharmacy cost$1.77 to $2.25 before shipping; $2.19 to $3.50 with shippingNo current UK price foundAbout $1.25 pharmacy acquisition cost (NADAC)

There is no FDA-approved fluticasone nebuliser product, so there is no US NADAC price to compare. NADAC is what US pharmacies pay, not a retail price; the budesonide figure is the generic rate of $0.62672 per mL (effective 21 October 2026) times the 2 mL fill. Budesonide is not the same medicine and the doses do not swap one for one: the UK fluticasone label says fluticasone propionate is about as effective as other inhaled steroids at roughly half the microgram daily dose (100 micrograms of fluticasone propionate is about equivalent to 200 micrograms of budesonide). In the US, fluticasone propionate is approved as metered-dose inhalers and dry powder inhalers. If you are in the US or Canada, ask your doctor whether a licensed inhaler with a spacer, or licensed budesonide nebuliser suspension, would suit you before ordering an unregistered product from abroad.

The UK label estimates that a smaller share of each nebulised dose reaches the bloodstream than with the inhaler: systemic availability in healthy volunteers was estimated at 8% for nebulised fluticasone propionate against up to 26% for the metered-dose inhaler (UK label 5.2). Nebuliser doses are much larger than inhaler doses, so this does not mean less steroid reaches the body overall (our note).

Which strength to choose

The UK label sets one dose range for adults and one fixed dose for children. This table turns each labelled dose into 0.5 mg respules a day (our arithmetic):

Label doseWho (UK label 4.1, 4.2)Flohale 0.5 respules
500 micrograms twice daily (lowest dose in the range)Adults and adolescents over 16, severe chronic asthma1 respule twice a day
1000 micrograms twice dailyAdults and adolescents over 162 respules twice a day
2000 micrograms twice daily (highest dose in the range)Adults and adolescents over 164 respules twice a day, or one Flohale 2mg respule twice a day
1000 micrograms twice dailyChildren and adolescents 4 to 16, flare-ups of asthma only2 respules twice a day

The UK label says the dose "may be increased until control is achieved or reduced to the minimum effective dose" and "should be titrated down to the lowest dose at which effective control of asthma is maintained". The Irish label, which unlike the UK label also lists flare-ups in adults and adolescents over 16, recommends a dose at the upper end of the adult range for flare-ups for up to 7 days, after which a lower dose should be considered. The dose, and any change to it, is your doctor's decision. Other fluticasone respiratory products in our range include the Seroflo 250 Inhaler (fluticasone with salmeterol) and the Maxiflo 125 Inhaler (fluticasone with formoterol); the budesonide nebuliser option is Budecort 0.5mg Respules.

Who the nebuliser form is for

The UK label licenses Flixotide Nebules for two groups only:

  • Adults and adolescents over 16: "prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy". The label says many people on steroid tablets may be able to reduce significantly, or stop, their tablet dose.
  • Children and adolescents 4 to 16: "Treatment of acute exacerbations of asthma". The label adds that "subsequent maintenance dosing may be more conveniently accomplished using a pressurised metered dose inhaler or powder formulation".

So it is not a first preventer for mild asthma, and for a child it is a treatment for a flare-up that a doctor starts and supervises, with maintenance usually moved to an inhaler (our reading of the UK label). A child having an asthma flare-up needs to be seen by a doctor now (our advice), not to wait 7 to 14 business days for a parcel. Some Indian listings (Apollo) mention COPD; the UK label does not list COPD as an indication, and it reports more pneumonia in people with COPD (see side effects). The UK and Irish labels do not cover children under 4; Apollo says safety and effectiveness under 4 have not been established.

How to use Flohale respules with a nebuliser

These steps follow the UK Flixotide Nebules label and leaflet. Follow the Cipla leaflet in the pack and your nebuliser maker's instructions as well.

  1. Use a jet nebuliser connected to an air compressor. The UK label says use with ultrasonic nebulisers is "not generally recommended", and that it "should not be injected or administered orally".
  2. Use a mouthpiece if you can. The UK label says this avoids "the possibility of atrophic changes to facial skin which may occur with prolonged use with a face-mask". If a face mask is used, protect the exposed skin with a barrier cream or wash the face thoroughly after treatment.
  3. Break one respule off the strip and keep the rest in their foil wrap, inside the carton.
  4. Mix the contents well. The UK label says to hold the nebule horizontally by the labelled tab, flick the other end a few times and shake, and repeat this several times until the contents are completely mixed.
  5. Twist off the tab, put the open end into the nebuliser bowl and squeeze slowly to empty it. If your dose is more than one respule, repeat with the next one.
  6. Do not dilute it unless your doctor tells you to; if you are told to, use only sterile sodium chloride 0.9% solution (UK leaflet).
  7. Breathe in the mist in a well-ventilated room, because some of the mist is released into the air and may be breathed in by others. Do not let the liquid or the mist get into your eyes; the UK leaflet says glasses or goggles can protect them.
  8. Afterwards, rinse your mouth with water, or brush your teeth or gargle, and spit it out: the UK leaflet says this reduces mouth and throat problems such as thrush and hoarseness. Throw away any liquid left in the respule or the bowl, and clean the nebuliser as its maker describes.

Use it every day at regular times, even when there are no symptoms. If you forget a dose, the UK leaflet says take the next dose when it is due and do not take a double dose. Do not stop it without talking to your doctor: the UK label says treatment "should not be stopped abruptly".

Storage: the UK label says do not store above 30°C, keep it in the outer carton to protect from light, do not freeze, and store upright. Once nebules are removed from their foil wrap they should be used within 28 days, and an opened nebule should be used immediately. Indian listings for Flohale say store below 30°C (Truemeds) or at 20 to 25°C (Apollo), and in the original packing (PharmEasy). We have not confirmed whether the Indian packet is foil wrapped or what its opened-pack period is: follow the Cipla leaflet, and if it gives none, using respules within 28 days of taking them out of their wrapping (the UK rule) is our cautious suggestion. Our parcels are not temperature controlled; if respules arrive frozen, or the suspension will not mix when shaken, contact us before using them. Our guide to respules, inhalers and Rotacaps explains when a nebuliser is worth it and when an inhaler with a spacer works as well.

Groups who need extra care

  • Coming off steroid tablets: the UK label says people transferred from steroid tablets "remain at risk of impaired adrenal reserve for a considerable time", that tablets should be reduced gradually at not less than weekly intervals, and that people whose adrenal function is still impaired should carry a steroid warning card. The US label for fluticasone propionate inhalers warns that deaths due to adrenal insufficiency have occurred during and after transfer from steroid tablets to inhaled steroids.
  • High doses for long periods: the UK label says prolonged high doses may cause adrenal suppression and acute adrenal crisis, and that "Children aged < 16 years taking higher than licensed doses of fluticasone (typically ≥1000mcg/day) may be at particular risk". Note that the licensed nebuliser dose for children aged 4 to 16 (1000 micrograms twice daily) is 2000 micrograms a day, and the UK label licenses it only for flare-ups (our note). Triggers include trauma, surgery, infection or any rapid reduction in dose; extra steroid cover should be considered during periods of stress or planned surgery.
  • Children: the UK label recommends regular height checks for children on prolonged inhaled steroids, a dose review if growth slows, and consideration of referral to a paediatric respiratory specialist.
  • Diabetes: the UK label reports very rare rises in blood glucose and says this should be considered in people with a history of diabetes.
  • Weak bones, or risk factors for them (long immobility, family history of osteoporosis, menopause, smoking, older age, poor nutrition, long-term anticonvulsants or steroid tablets): the US inhaler label says these patients should be monitored and treated to established standards of care.
  • Eye problems: the UK label says a person with blurred vision or other visual disturbances should be considered for referral to an ophthalmologist, as causes may include cataract, glaucoma or central serous chorioretinopathy. The US inhaler label says glaucoma, raised eye pressure and cataracts have been reported with long-term inhaled steroids, including fluticasone propionate.
  • Liver or kidney problems, older people: the UK label says there is no need to adjust the dose.
  • Pregnancy: the UK label says use "should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus". In a UK health records study of 5,362 pregnancies exposed to inhaled steroids in the first trimester, the adjusted odds ratio for major birth defects with fluticasone propionate against other inhaled steroids was 1.1 (95% CI 0.5 to 2.3) in moderate asthma and 1.2 (95% CI 0.7 to 2.0) in considerable to severe asthma (UK label 5.1). Treatment should not be stopped abruptly.
  • Breastfeeding: the UK label says passage into human milk has not been studied, blood levels at recommended inhaled doses are likely to be low, and use "should only be considered if the expected benefit to the mother is greater than any possible risk to the child".

Medicines that interact:

  • Ritonavir (and HIV medicines boosted with it): the UK label says ritonavir "can greatly increase the concentration of fluticasone propionate in plasma". In a study with fluticasone nasal spray, ritonavir 100 mg twice daily raised fluticasone levels several hundred fold and markedly lowered cortisol; cases of Cushing's syndrome and adrenal suppression have been reported. The UK label says the combination "should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects".
  • Ketoconazole, itraconazole and other potent CYP3A inhibitors: in a small study ketoconazole raised fluticasone exposure after a single inhalation by 150% and lowered cortisol further. For itraconazole and similar drugs the UK label says "Caution is recommended and long-term treatment with such drugs should if possible be avoided". For potent CYP3A inhibitors including cobicistat-containing products, it says they are expected to increase the risk of systemic side effects and that combinations "should be avoided unless the benefit outweighs the potential increased risk", with monitoring. The US label for fluticasone propionate inhalers says the use of strong CYP3A4 inhibitors (for example ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) "is not recommended because increased systemic corticosteroid adverse effects may occur".
  • The UK label says erythromycin gives a negligible increase in exposure. Tell your doctor about every medicine you take, including medicines bought without a prescription and herbal medicines (UK leaflet).

Side effects

The UK label lists side effects by frequency, not as trial percentages. This table gives every item in the UK Flixotide Nebules list (section 4.8):

How often (UK label)Side effect
Very common (more than 1 in 10)Thrush (candidiasis) of the mouth and throat
Common (up to 1 in 10)Hoarseness or voice change; pneumonia (in people with COPD); bruising (contusions). The UK leaflet also lists sore tongue or throat as common.
Uncommon (up to 1 in 100)Allergic skin reactions
Rare (up to 1 in 1,000)Thrush of the oesophagus
Very rare (up to 1 in 10,000)Angioedema (mainly facial and throat swelling); breathlessness or bronchospasm as allergy signs; anaphylactic reactions; Cushing's syndrome and Cushingoid features, adrenal suppression, slowed growth in children and adolescents, lower bone mineral density, cataract, glaucoma; raised blood glucose; anxiety, sleep problems and behaviour changes including hyperactivity and irritability (mainly in children); wheezing straight after a dose (paradoxical bronchospasm); indigestion; joint pain
Not knownBlurred vision; depression and aggression (mainly in children); nosebleeds

Source: UK Flixotide Nebules label 4.8. The label says hoarseness and thrush occur in some patients, who "may find it helpful to rinse out their mouth with water after inhalation from the nebuliser", and that thrush can be treated with an antifungal while carrying on with the nebules. It also says doctors should watch for pneumonia in people with COPD, because the signs of pneumonia and of a COPD flare often overlap. The UK leaflet lists pneumonia warning signs as more sputum, a change in sputum colour, fever, chills, more cough and more breathing problems.

Growth in children. The US label for fluticasone propionate inhalers says inhaled steroids may cause a reduction in growth velocity in children and advises routine growth checks (for example with a stadiometer). The UK label says to monitor height regularly and, if growth is slowed, review the dose with the aim of reducing it to the lowest dose that keeps asthma controlled.

We have not added a chart: the UK label gives frequency bands only, with no placebo-controlled percentages for the nebuliser form.

When to get urgent help

  • A severe asthma attack, or one that your reliever does not help: call emergency services now (911 in the US and Canada, 999 in the UK, 000 in Australia; this is our advice). Flohale will not relieve an attack. The UK leaflet says: "If your breathing suddenly gets worse, this can be life-threatening so seek medical advice urgently."
  • Wheezing or breathing that gets worse straight after a dose (paradoxical bronchospasm): use a fast-acting reliever now and stop Flohale. The UK label says it should be treated immediately with a fast-acting bronchodilator and the nebules stopped immediately.
  • Swelling of the face, lips, mouth, tongue or throat, trouble swallowing or breathing, an itchy rash, feeling faint or collapse: signs of a severe allergic reaction. The UK leaflet says stop using it and talk to your doctor straight away, as you may need urgent medical treatment.
  • Being unwell with vague symptoms such as loss of appetite, tummy pain, weight loss, tiredness, headache, nausea or vomiting, drowsiness or confusion, low blood sugar or a fit, especially in someone on high doses, during an infection or after a dose cut: the UK label lists these as signs of acute adrenal crisis. If the person is drowsy or confused, has a fit, or keeps vomiting, call emergency services now; otherwise get medical help the same day, and tell the doctor about the steroid (our advice). The UK leaflet says not to stop the steroid suddenly.
  • Someone on Flohale who has not had chickenpox or measles, or been properly immunised, and is exposed to either: the US inhaler label says these infections can have a more serious or even fatal course in people using corticosteroids. Contact a doctor without delay (our advice).
  • Your reliever works less well than before, or you need it more often than usual: the UK label says "medical attention must be sought". The UK leaflet also says to talk to your doctor as soon as possible if your breathing has not improved, or has got worse, after 7 days of treatment.

If too many respules are used: the UK label says an acute overdose may temporarily suppress adrenal function, which "does not need emergency action" because it recovers in a few days, and the UK leaflet says talk to your doctor as soon as possible. Using more than the recommended dose for a long time may cause adrenal suppression (UK label 4.9). Tell any doctor treating you what you use, how much and since when.

Who should not use Flohale 0.5 Respules

Never use it (contraindication, UK label 4.3):

  • if you are allergic to fluticasone propionate or any ingredient of the respules.

Not for (UK label 4.4):

  • relieving sudden symptoms, or replacing steroid tablets or injections in a life-threatening attack.

Use with caution, if at all (US label for fluticasone propionate inhalers, 5.3):

  • active or quiescent tuberculosis of the airways; fungal, bacterial, viral or parasitic infections throughout the body; or herpes infection of the eye. The UK label says special care is necessary in people with active or quiescent lung tuberculosis.

Avoid unless your doctor decides the benefit outweighs the risk (UK label 4.4, 4.5):

  • ritonavir, cobicistat-containing products and other potent CYP3A inhibitors; for itraconazole-type drugs the UK label recommends caution and avoiding long-term combined use if possible (the US inhaler label says strong CYP3A4 inhibitors are "not recommended"; see above).

Talk to a doctor first:

  • if you are coming off steroid tablets, have diabetes, weak bones or eye problems, have COPD, are pregnant or breastfeeding, or the patient is a child (see above);
  • if you have ever been treated for tuberculosis (UK leaflet);
  • if you have not had chickenpox or measles or been immunised against them;
  • if you are planning surgery, since extra steroid cover may be needed (UK label 4.4).

Prescription and legal status

Fluticasone propionate for inhalation is a prescription medicine in the US (inhalers and powders only; there is no FDA-approved nebuliser form), Canada (all fluticasone propionate inhalers in Health Canada's Drug Product Database are prescription products; no nebuliser form is listed) and Australia (healthdirect lists Flixotide Nebules as a Schedule 4 prescription only medicine). In the UK, Flixotide Nebules hold a marketing authorisation (PL 10949/0297), but the NHS dictionary of medicines and devices lists the GSK 0.5 mg pack, and a parallel-imported pack, as discontinued and not available, and the emc lists no fluticasone nebuliser product. Indian listings mark Flohale as prescription only (Apollo, PharmEasy and Truemeds). This Indian Flohale pack is not registered with the FDA, the MHRA, the TGA or Health Canada, and in the US the FDA says personal importation of unapproved medicines is illegal in most circumstances. The UK label says severe asthma "requires regular medical assessment, including lung function testing"; a written asthma action plan helps too (our advice). Check the rules where you live.

Buying genuine Flohale

The MHRA warns: "Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have." It also advises: "Only use UK-registered pharmacies, including online pharmacies displaying the official green cross logo." That warning covers this Indian Flohale pack. When your order arrives, check that the packets and respules name Cipla, Flohale and fluticasone propionate 0.5 mg in 2 mL, with a batch number and an expiry date, and that the respules are sealed. These checks cannot prove a product is genuine, because counterfeiters copy packaging. If asthma control gets worse after switching supply, see a doctor rather than taking extra doses. If a batch causes unusual symptoms, seek medical advice and report it to your medicines regulator (the MHRA Yellow Card scheme in the UK, FDA MedWatch in the US, the TGA in Australia or Health Canada) as well as to us.

Delivery

We ship Flohale 0.5 Respules to the US, UK, Australia and Canada in plain packaging with tracking. Standard delivery takes 7 to 14 business days to most countries, so order at least three weeks before your current supply runs out: a preventer works only if it is used every day. Shipping costs a flat $25 on orders under $149 and is free from $149. See our shipping page and refund policy.

Related guides

Sources

  • Flixotide Nebules 0.5 mg/2 ml, UK summary of product characteristics (date of revision 16 November 2023) and patient leaflet (revised August 2020), Glaxo Wellcome UK Ltd trading as GlaxoSmithKline UK, PL 10949/0297, sections 4.1 to 4.9, 5.1, 5.2, 6.3, 6.4 and 6.6. MHRA Products
  • Flixotide Nebules 0.5 mg/2ml, Irish summary of product characteristics, PA1077/044/016, text dated 8 October 2019, section 4.2. HPRA
  • Fluticasone propionate inhalation aerosol, Glenmark, US prescribing information, DailyMed setid 27a9b531-f0fd-44ee-b197-ac4b7d64b30c, version 2, effective 25 March 2026, sections 1, 5.2 to 5.4, 5.7 to 5.9 and 5.11. DailyMed
  • US Food and Drug Administration, Drugs@FDA via openFDA: products containing fluticasone propionate, queried 21 October 2026. openFDA
  • Health Canada Drug Product Database: fluticasone propionate products, searched 21 October 2026. Health Canada DPD
  • NHS Business Services Authority, dm+d: Flixotide 0.5mg/2ml Nebules (GlaxoSmithKline UK Ltd), accessed 21 October 2026. dm+d
  • healthdirect Australia: Flixotide Nebules 0.5mg/2mL inhalation ampoule, accessed 21 October 2026. healthdirect
  • Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC), budesonide 0.5 mg/2 mL inhalation suspension, rates effective 21 October 2026. data.medicaid.gov
  • Apollo Pharmacy, PharmEasy and Truemeds. Flohale 0.5mg Respules (Cipla) listings, accessed 21 October 2026. PharmEasy
  • MHRA. 20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys, 13 February 2026. GOV.UK
  • US Food and Drug Administration. Personal Importation. FDA

This page is for information and is not medical advice. Fluticasone propionate is a prescription medicine; your doctor should set the dose and the asthma action plan, especially for a child.

Frequently asked questions

What is Flohale 0.5 Respules?

Flohale 0.5 Respules are single-dose ampoules of fluticasone propionate nebuliser suspension made in India by Cipla. Indian pharmacy listings give each respule as fluticasone propionate 0.5 mg in 2 mL, in packets of 5. Fluticasone propionate is an inhaled corticosteroid preventer, breathed in as a mist through a jet nebuliser. It is not a reliever: keep a fast-acting reliever such as salbutamol for sudden symptoms.

Is Flohale the same as Flixotide Nebules?

Both contain fluticasone propionate 0.5 mg in 2 mL for nebulisation, but they are different products from different makers (Cipla in India, GSK in the UK). We have not found a published study comparing them. Flixotide Nebules hold a UK licence, although the NHS dictionary of medicines lists the GSK 0.5 mg pack as discontinued and not available. This Indian Flohale pack is not registered with the FDA, MHRA, TGA or Health Canada.

How much does Flohale 0.5 cost per respule?

As of October 2026, $2.25 a respule in the 20 pack ($45.00), $1.81 in the 40 pack ($72.50) and $1.77 in the 60 pack ($106.25), before shipping. Shipping is $25 under $149, so with shipping that is $3.50, $2.44 and $2.19 a respule. The pack selector shows the current price. There is no FDA-approved fluticasone nebuliser product, so there is no US pharmacy cost to compare.

How do I use Flohale respules?

Use a jet nebuliser with a compressor, preferably with a mouthpiece; the UK label says ultrasonic nebulisers are not generally recommended. Mix the respule well by flicking and shaking it, twist off the tab, squeeze all the contents into the nebuliser bowl and breathe in the mist in a well-ventilated room, keeping the mist out of your eyes. Afterwards rinse your mouth, brush your teeth or gargle with water and spit it out. If you use a face mask, protect or wash your face. Throw away any leftover liquid.

How many Flohale 0.5 respules a day?

Your doctor decides. The UK Flixotide Nebules label gives 500 to 2000 micrograms twice daily for adults and adolescents over 16 with severe chronic asthma, which is 1 to 4 respules twice a day (2 to 8 a day). For children and adolescents aged 4 to 16 it gives 1000 micrograms twice daily for asthma flare-ups only, which is 2 respules twice a day. The respule counts are our arithmetic.

How long does Flohale take to work?

It is a preventer, not a quick reliever. The UK leaflet says it takes a few days to work and that it is very important to use it regularly. The Irish Flixotide Nebules label says maximal improvement may be reached within 4 to 7 days, with some effect as soon as 24 hours in people not previously on inhaled steroids. The UK leaflet says talk to your doctor if your breathing has not improved, or is worse, after 7 days.

Can children use Flohale respules?

The UK label licenses the nebuliser form in children and adolescents aged 4 to 16 only for treating asthma flare-ups, at 1000 micrograms twice daily, and says later maintenance may be more conveniently given with an inhaler or powder. It does not cover children under 4. A child having a flare-up needs a doctor now, not a parcel that takes 7 to 14 business days (our advice). Children on inhaled steroids should have their height checked regularly.

What are the side effects of Flohale respules?

In the UK Flixotide Nebules label, thrush of the mouth and throat is very common, and hoarseness, bruising and (in people with COPD) pneumonia are common. Rare and very rare effects include thrush of the oesophagus, severe allergic reactions, wheezing straight after a dose, adrenal suppression, slowed growth in children, lower bone density, cataract, glaucoma, raised blood glucose and behaviour changes mainly in children. Blurred vision, nosebleeds, depression and aggression have also been reported. Rinsing the mouth after each dose helps.

Who should not use Flohale 0.5 Respules?

Do not use it if you are allergic to fluticasone propionate or any ingredient (UK label 4.3), or to relieve a sudden attack. The US label for fluticasone propionate inhalers says inhaled steroids should be used with caution, if at all, in active or quiescent tuberculosis, systemic fungal, bacterial, viral or parasitic infections, or herpes infection of the eye. The UK label says ritonavir, cobicistat-containing products and other potent CYP3A inhibitors should be avoided unless the benefit outweighs the risk, and recommends caution and avoiding long-term use with itraconazole-type drugs. Talk to a doctor first if you are coming off steroid tablets, have diabetes, weak bones, eye problems or COPD, or are pregnant or breastfeeding.

Do I need a prescription for Flohale?

Yes. Fluticasone propionate for inhalation is prescription only in the US, Canada, the UK and Australia, and Indian listings (Apollo, PharmEasy, Truemeds) mark Flohale as prescription only. The nebuliser form is not approved in the US or Canada. This Indian pack is not registered with the FDA, MHRA, TGA or Health Canada, and the FDA says personal importation of unapproved medicines is illegal in most circumstances. Check the rules where you live.

How long does delivery take?

Standard delivery takes 7 to 14 business days to the US, UK, Australia and Canada, in plain packaging with tracking. Shipping is a flat $25 on orders under $149 and free from $149. Order at least three weeks before your current supply runs out, because a preventer works only if it is used every day. Our parcels are not temperature controlled: if respules arrive frozen, contact us before using them.

Medical References

  1. 1.OpenFDA Drug Label (U.S. FDA)
  2. 2.ClinicalTrials.gov NCT01168310
  3. 3.ClinicalTrials.gov NCT00883168
  4. 4.ClinicalTrials.gov NCT05179512

Sources: U.S. National Library of Medicine (DailyMed, PubMed), openFDA

Guide to AsthmaHow asthma medicines actually work: relievers, inhaled steroids, combination inhalers and leukotriene tablets, with the 2019 guideline change that ended reliever-only treatment.

Related articles

Customer Reviews

No reviews yet. Bought Flohale 0.5 Respules? Tell other buyers how it went.